Navigation Links
FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
Date:7/14/2008

Data Provides Further Information on AVANDIA as a Safe and Effective

Treatment Option for Appropriate Type 2 Diabetes Patients

PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announces today that the U.S. Food and Drug Administration (FDA) updated the prescribing information for AVANDIA(R) (rosiglitazone maleate) to include clinical findings from A Diabetes Outcome Progression Trial (ADOPT), a 4- to- 6 year head-to-head study of AVANDIA versus metformin and glyburide monotherapy in recently diagnosed type 2 diabetes patients. The percentage of patients with inadequate glucose control at five years was 34 percent with glyburide, 21 percent with metformin and only 15 percent with AVANDIA. The difference between AVANDIA and the comparators was statistically significant.

"GSK is pleased that the FDA has approved inclusion of the results from ADOPT, an important clinical trial that provides substantial long-term efficacy and safety data on AVANDIA compared to metformin and sulfonylurea," said Alexander R. Cobitz, MD, PhD, Senior Director, Metabolism, Clinical Development and Medical Affairs, GlaxoSmithKline. "As demonstrated in this study, patients treated with AVANDIA achieved greater sustained glycemic control. Better glycemic control has been proven to reduce risks of serious complications associated with type 2 diabetes including blindness, loss of limbs and kidney failure."

Study Design

ADOPT was a large, international, multi-center, randomized, double-blind, parallel-group study involving 4,351 people, aged 30-75 years who were recently diagnosed with type 2 diabetes (less than or equal to 3 years) from more than 400 sites throughout North America and Europe. ADOPT, conducted over a period of 4 to 6 years, assessed the cumulative incidence of monotherapy failure at five years with AVANDIA, metformin, glyburide, as defined by consecutive fasting plasma glucose (FPG) >180 mg/dL.

Patients
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. BioCryst Updates Peramivir Clinical Development Plan
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... of Powers Lake, Wisconsin , ... a distribution and co-marketing agreement allowing ScriptPro to ... throughout the United States . ... management and workflow systems to retail and ambulatory ...
(Date:7/25/2014)... WASHINGTON , July 25, 2014 Cardinal ... innovative community pharmacies as winners of its prestigious Independent ... Business Conference , one of the nation,s largest gatherings ... Competition winners – family-owned pharmacies from Ohio ... Texas – were selected for implementing ...
(Date:7/25/2014)... 25, 2014 Research and Markets ... Diagnostic Devices Market 2014-2018" report to their offering. ... About Ophthalmic Diagnostic Device An ophthalmic ... a defect or deficiency in the human visual pathway. ... such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... March of Dimes Message: Start Taking a Vitamin with ... Women who take folic acid supplements for at least ... risk of having a premature baby by half, according ... PLOS Medicine.The study links pre-conceptional folate supplementation of at ...
... Results of its Clinical Study of LT-NS001 vs. naproxen ... Logical Therapeutics, Inc (Logical), a biotechnology company focused on ... inflammation, today announced that Peter A. Lankau has been ... the Company,s Board of Directors. Mr. Lankau was ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 3Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 4
(Date:7/27/2014)... 1-Butene is a colorless, combustible gas with a characteristic ... manufactured either through the separation from crude C4 refinery ... olefin (alkene) 1-Butene is a versatile chemical that can ... such as linear light density polyethylene (LLDP), polybutene-1, valeraldehyde, ... is extremely competitive. The market has several market participants ...
(Date:7/27/2014)... Bromine market report defines and segments the Bromine market in ... in European region comprises of four major countries. They are ... a dominant share of Bromine market influences the demand for ... the TOC of the Europe Bromine Market report, to get ... TOC of the Europe Bromine Market report. The report provides ...
(Date:7/27/2014)... As Tylenol lawsuits ( ... forward in federal court, Bernstein Liebhard LLP notes ... the benefits purportedly associated with acetaminophen, the active ... appears in the The Lancet, looked at 1,643 ... were given either acetaminophen or a placebo for ...
(Date:7/27/2014)... 27, 2014 (HealthDay News) -- Couples aren,t more likely ... than the husband, new research finds. The study ... that education levels play a direct role in affecting ... Still, "our results speak against fears that women,s growing ... marital stability," Christine Schwartz, lead author of the study, ...
(Date:7/27/2014)... July 27, 2014 iFitDress.com, a well-known ... latest range of wedding gowns with sleeves . ... elegant items; they are now available with big discounts, ... is true that iFitDress.com is one of the big ... sales representative, the new wedding gowns feature fine craftsmanship ...
Breaking Medicine News(10 mins):Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 2Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 3Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 4Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2
... EDAP TMS S.A. (Nasdaq:,EDAP) the global leader ... announces that it has entered into a securities ... buyers,("Investors") pursuant to which the Investors will purchase ... EDAP,s ordinary shares,which will be delivered in the ...
... BOSTON, Oct. 30 Portrayals of bipolar,disorder seem ... news, in movies, and,on television. The November 2007 ... and misunderstandings about this condition., Bipolar disorder ... confused,with other mental illnesses. Because mania is the ...
... was,released today by the Center for Consumer Freedom:, ... the results of a five-year examination of various causes ... expected to recommend,limiting human intake of specific foods, including ... for Consumer Freedom is,available to discuss the implications of ...
... Down syndrome infants on treadmill training for just minutes ... or five months earlier than with only traditional physical ... says. , The study also suggests that infants who ... , Getting infants walking is critical because so ...
... children with dyslexia struggle to read because their ... according to a brain-imaging study published this month ... October 16). The study found that sound training ... correcting the sound processing problem and improving reading. ...
... California will simultaneously open their doors Wednesday to ... cover the,festivities, SAN FRANCISCO, Oct. 30 It,s ... Nurse administrators don,t often,see miniature witches and 3-foot-tall bumblebees, ... 80-year-young ballerinas! But at more,than 150 nursing homes in ...
Cached Medicine News:Health News:EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies 2Health News:EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies 3Health News:Misconceptions About Bipolar Disorder Explained, From the Harvard Health Letter 2Health News:Treadmill training helps Down syndrome babies walk months earlier 2Health News:Sound training rewires dyslexic children's brains for reading 2Health News:Sound training rewires dyslexic children's brains for reading 3Health News:Halloween Events in the Bay Area Bring Young and Old Together for a Ghoulish Good Time 2
... Techno-Aide provides the highest level ... highest quality lead protective eyewear. ... + tolerance allowed. Mfg supervised by ... All lens meet or exceed standards ...
This Flex Goggle has a unique wrap around design which fits the contour of the face and brow for optimum coverage. The ratchet style temple hinge allows multiple adjustments in, out, up and down for...
... constructed of extremely durable nylon that exhibits ... The molded wrap around feature provides maximum ... distribute weight evenly over the nose while ... side shields. Also available with adjustable ...
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
Medicine Products: